Pancreatic Cancer Research

ResearcherIndiana University HealthActive in the last 2 years

Nicholas Joseph Zyromski

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5025-2439; OpenAlex author ID A5081374178. Sources: OpenAlex.

Their work

Papers
22 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
62
Papers, trials and grants by year

2011: 2 papers · 2012: 2 papers · 2013: none · 2014: none · 2015: 1 paper · 2016: 4 papers · 2017: 1 paper · 2018: 1 paper · 2019: 3 papers · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 22

  1. Staging laparoscopy to detect occult metastases in localized pancreatic cancer: global survey among nine international societies. Co-author DOI 10.1016/j.hpb.2025.12.001↗
  2. Rediscover: An Italian and international consensus meeting on locally advanced pancreatic cancer. Co-author DOI 10.1016/j.sopen.2023.11.001↗
  3. Patients with deleterious germline mutations: A heterogeneous population for pancreatic cancer screening? Co-author DOI 10.1002/jso.27289↗
  4. Neoadjuvant therapy at local versus outside institutions does not adversely impact surgical timing or long-term outcomes in patients with pancreatic adenocarci… Co-author DOI 10.1016/j.surg.2022.06.046↗
  5. 2021 SSAT Debate: Selective Approach to Resection of the Superior Mesenteric Artery in Pancreatic Cancer vs Superior Mesenteric Artery Encasement Is Not an Abs… Last author DOI 10.1007/s11605-021-05237-1↗
  6. Profiling of Adipose and Skeletal Muscle in Human Pancreatic Cancer Cachexia Reveals Distinct Gene Profiles with Convergent Pathways. Co-author DOI 10.3390/cancers13081975↗
  7. Hepatic Steatosis After Neoadjuvant Chemotherapy for Pancreatic Cancer: Incidence and Implications for Outcomes After Pancreatoduodenectomy. Co-author DOI 10.1007/s11605-020-04723-2↗
  8. Pancreatic Adenocarcinoma Causing Necrotizing Pancreatitis: Not as Rare as You Think? Last author DOI 10.1016/j.jss.2019.12.036↗
  9. The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy. Co-author DOI 10.1002/jcsm.12461↗
  10. Are BRCA1 and BRCA2 gene mutation patients underscreened for pancreatic adenocarcinoma? Co-author DOI 10.1002/jso.25376↗
  11. Phase 1 study of EUS-guided photodynamic therapy for locally advanced pancreatic cancer. Co-author DOI 10.1016/j.gie.2018.09.007↗
  12. Laparoscopic distal pancreatectomy for pancreatic cancer is safe and effective. Co-author DOI 10.1007/s00464-017-5633-7↗
  13. Prospective Evaluation of Associations between Cancer-Related Pain and Perineural Invasion in Patients with Resectable Pancreatic Adenocarcinoma. Co-author DOI 10.1007/s11605-017-3513-z↗
  14. Significance of Portal Vein Invasion and Extent of Invasion in Patients Undergoing Pancreatoduodenectomy for Pancreatic Adenocarcinoma. Co-author DOI 10.1007/s11605-015-3005-y↗
  15. A systematic review of the role of periadventitial dissection of the superior mesenteric artery in affecting margin status after pancreatoduodenectomy for panc… Last author DOI 10.1016/j.hpb.2015.11.009↗
  16. Adipocytes enhance murine pancreatic cancer growth via a hepatocyte growth factor (HGF)-mediated mechanism. Last author DOI 10.1016/j.ijsu.2016.03.002↗
  17. Regulation of HIF1α under Hypoxia by APE1/Ref-1 Impacts CA9 Expression: Dual Targeting in Patient-Derived 3D Pancreatic Cancer Models. Co-author DOI 10.1158/1535-7163.mct-16-0253↗
  18. Extended distal pancreatectomy for pancreatic adenocarcinoma with splenic vein thrombosis and/or adjacent organ invasion. Co-author DOI 10.1016/j.amjsurg.2014.10.017↗
  19. Autoimmune pancreatitis (AIP) masquerading as pancreatic cancer: cutting is not a crime … for now. Co-author DOI 10.1007/s10620-012-2285-2↗
  20. Obesity, but not high-fat diet, promotes murine pancreatic cancer growth. Last author DOI 10.1007/s11605-012-1931-5↗
  21. Does the interval from imaging to operation affect the rate of unanticipated metastasis encountered during operation for pancreatic adenocarcinoma? Co-author DOI 10.1016/j.surg.2011.07.048↗
  22. Pancreatic cancer in obesity: epidemiology, clinical observations, and basic mechanisms. Co-author DOI 10.2174/187152011795677445↗

Closest collaborators

The 25 strongest of 62 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael Garrett House · 13 shared papers, 2011–2023 · strength 1.26
  2. Eugene P. Ceppa · 11 shared papers, 2015–2023 · strength 1.14
  3. Christian Max Schmidt · 9 shared papers, 2015–2023 · strength 0.85
  4. Ugo Boggi · 2 shared papers, 2022–2024 · strength 0.72
  5. Alexandra M. Roch · 6 shared papers, 2015–2023 · strength 0.66
  6. Trang K. Nguyen · 3 shared papers, 2020–2023 · strength 0.47
  7. Mark Joseph Truty · 2 shared papers, 2022–2026 · strength 0.46
  8. Rachel C. Kim · 2 shared papers, 2023 · strength 0.37
  9. Safi Shahda · 4 shared papers, 2016–2021 · strength 0.32
  10. Christopher M. Schmidt · 3 shared papers, 2011–2023 · strength 0.32
  11. Matthew H. G. Katz · 2 shared papers, 2016–2026 · strength 0.28
  12. Henry Anthony Pitt · 4 shared papers, 2011–2018 · strength 0.21
  13. Rutger T. Theijse · 1 shared paper, 2026 · strength 0.20
  14. Sohei Satoi · 1 shared paper, 2026 · strength 0.20
  15. Ingmar Florin Rompen · 1 shared paper, 2026 · strength 0.20
  16. John M. Primrose · 1 shared paper, 2026 · strength 0.20
  17. Patrik Larsson · 1 shared paper, 2026 · strength 0.20
  18. Thilo Hackert · 1 shared paper, 2026 · strength 0.20
  19. Atsushi Oba · 1 shared paper, 2026 · strength 0.20
  20. Shailesh Vinayak Shrikhande · 1 shared paper, 2026 · strength 0.20
  21. José Manuel Ramia · 1 shared paper, 2026 · strength 0.20
  22. Bas Groot Koerkamp · 1 shared paper, 2026 · strength 0.20
  23. Poya Ghorbani · 1 shared paper, 2026 · strength 0.20
  24. Thomas F. Stoop · 1 shared paper, 2026 · strength 0.20
  25. Elena B. Rangelova · 1 shared paper, 2026 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.